Therefore, a low-dose anti-PD-1 antibody was utilized in our regime for its capacity to address the immunosuppressive tumor microenvironment as a replacement of IL-2 [23] rather than its conventional antitumor activity. The gene discussed is PDCD1; the disease is neoplasm.